Nuvation Bio

NUVB · NYSE

$4.77+$0.29 (+6.47%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $4.48

Latest news

NewsSep 17, 12:46 PM ETVandana Singh
Why Is Nuvation Bio Stock Gaining Thursday?
Press releaseSep 17, 7:30 AM ETPRNewswire
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Press releaseSep 15, 8:00 AM ETPRNewswire
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
NewsSep 4, 7:07 AM ETAvi Kapoor
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
Press releaseSep 2, 4:05 PM ETPRNewswire
Nuvation Bio to Participate in Upcoming Investor Conferences
NewsAug 20, 8:05 AM ET
Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1
Press releaseAug 20, 8:00 AM ETPRNewswire
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Press releaseAug 6, 7:30 AM ETPRNewswire
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseAug 4, 8:00 AM ETPRNewswire
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Press releaseJul 22, 4:05 PM ETPRNewswire
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
NewsJul 20, 11:44 AM ETVandana Singh
Why Is Nuvation Bio Stock Gaining Monday?
NewsJul 20, 10:08 AM ETAvi Kapoor
AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday
Press releaseJul 20, 8:00 AM ETPRNewswire
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
Press releaseJul 6, 5:09 PM ETPRNewswire
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Press releaseJun 29, 8:00 AM ETPRNewswire
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
Press releaseJun 25, 11:58 PM ETPRNewswire
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
NewsJun 25, 8:08 AM ETAvi Kapoor
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Press releaseJun 25, 7:00 AM ETPRNewswire
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Press releaseMay 27, 4:05 PM ETPRNewswire
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Press releaseMay 27, 8:00 AM ETPRNewswire
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
Press releaseMay 13, 4:05 PM ETPRNewswire
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Press releaseMay 7, 10:56 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)
Press releaseMay 6, 8:00 AM ETPRNewswire
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Press releaseMay 5, 4:05 PM ETPRNewswire
Nuvation Bio to Participate in Upcoming Investor Conferences
NewsMay 4, 4:13 PM ET
Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.
Press releaseMay 4, 4:10 PM ETPRNewswire
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
NewsMay 4, 7:11 AM ET
Earnings Scheduled For May 4, 2026
Press releaseApr 27, 8:00 AM ETPRNewswire
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Press releaseApr 21, 6:00 PM ETPRNewswire
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
Press releaseApr 21, 6:00 PM ETPRNewswire
/U P D A T E -- Nuvation Bio Inc./
Press releaseApr 20, 4:05 PM ETPRNewswire
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
Press releaseApr 2, 1:19 PM ETPRNewswire
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Press releaseApr 1, 8:00 AM ETPRNewswire
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
Press releaseMar 4, 8:30 AM ETGlobe Newswire
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
NewsMar 3, 4:00 PM ET
Deep Dive Into Nuvation Bio Stock: Analyst Perspectives (7 Ratings)
NewsMar 3, 12:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMar 3, 8:04 AM ETAvi Kapoor
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Why Is Nuvation Bio Stock Gaining Thursday?

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Why Is Nuvation Bio Stock Gaining Monday?

AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session

Nuvation Bio Announces Proposed Convertible Senior Notes Offering

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Earnings Scheduled For May 4, 2026

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

/U P D A T E -- Nuvation Bio Inc./

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Deep Dive Into Nuvation Bio Stock: Analyst Perspectives (7 Ratings)

12 Health Care Stocks Moving In Tuesday's Intraday Session

MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session